S&P 500   2,613.32 (+2.83%)
DOW   22,180.64 (+2.51%)
QQQ   191.18 (+3.17%)
AAPL   253.92 (+2.49%)
FB   165.33 (+5.45%)
MSFT   159.78 (+6.73%)
GOOGL   1,141.43 (+2.81%)
AMZN   1,952.97 (+2.78%)
CGC   14.30 (-2.59%)
NVDA   263.42 (+4.23%)
BABA   189.77 (+0.63%)
MU   44.26 (+1.79%)
GE   7.89 (+3.41%)
TSLA   505.20 (-1.78%)
AMD   47.73 (+2.47%)
T   30.12 (+0.94%)
ACB   0.88 (-14.59%)
F   5.01 (-3.47%)
BAC   22.21 (+2.78%)
GILD   75.68 (+3.88%)
PRI   91.75 (+1.99%)
DIS   98.03 (+1.69%)
S&P 500   2,613.32 (+2.83%)
DOW   22,180.64 (+2.51%)
QQQ   191.18 (+3.17%)
AAPL   253.92 (+2.49%)
FB   165.33 (+5.45%)
MSFT   159.78 (+6.73%)
GOOGL   1,141.43 (+2.81%)
AMZN   1,952.97 (+2.78%)
CGC   14.30 (-2.59%)
NVDA   263.42 (+4.23%)
BABA   189.77 (+0.63%)
MU   44.26 (+1.79%)
GE   7.89 (+3.41%)
TSLA   505.20 (-1.78%)
AMD   47.73 (+2.47%)
T   30.12 (+0.94%)
ACB   0.88 (-14.59%)
F   5.01 (-3.47%)
BAC   22.21 (+2.78%)
GILD   75.68 (+3.88%)
PRI   91.75 (+1.99%)
DIS   98.03 (+1.69%)
S&P 500   2,613.32 (+2.83%)
DOW   22,180.64 (+2.51%)
QQQ   191.18 (+3.17%)
AAPL   253.92 (+2.49%)
FB   165.33 (+5.45%)
MSFT   159.78 (+6.73%)
GOOGL   1,141.43 (+2.81%)
AMZN   1,952.97 (+2.78%)
CGC   14.30 (-2.59%)
NVDA   263.42 (+4.23%)
BABA   189.77 (+0.63%)
MU   44.26 (+1.79%)
GE   7.89 (+3.41%)
TSLA   505.20 (-1.78%)
AMD   47.73 (+2.47%)
T   30.12 (+0.94%)
ACB   0.88 (-14.59%)
F   5.01 (-3.47%)
BAC   22.21 (+2.78%)
GILD   75.68 (+3.88%)
PRI   91.75 (+1.99%)
DIS   98.03 (+1.69%)
S&P 500   2,613.32 (+2.83%)
DOW   22,180.64 (+2.51%)
QQQ   191.18 (+3.17%)
AAPL   253.92 (+2.49%)
FB   165.33 (+5.45%)
MSFT   159.78 (+6.73%)
GOOGL   1,141.43 (+2.81%)
AMZN   1,952.97 (+2.78%)
CGC   14.30 (-2.59%)
NVDA   263.42 (+4.23%)
BABA   189.77 (+0.63%)
MU   44.26 (+1.79%)
GE   7.89 (+3.41%)
TSLA   505.20 (-1.78%)
AMD   47.73 (+2.47%)
T   30.12 (+0.94%)
ACB   0.88 (-14.59%)
F   5.01 (-3.47%)
BAC   22.21 (+2.78%)
GILD   75.68 (+3.88%)
PRI   91.75 (+1.99%)
DIS   98.03 (+1.69%)
Log in

NASDAQ:ZFGN - Zafgen Stock Price, Forecast & News

$0.81
+0.02 (+2.54 %)
(As of 03/30/2020 03:05 PM ET)
Today's Range
$0.71
Now: $0.81
$0.81
50-Day Range
$0.66
MA: $1.07
$1.32
52-Week Range
$0.62
Now: $0.81
$2.97
Volume13,416 shs
Average Volume139,605 shs
Market Capitalization$30.31 million
P/E RatioN/A
Dividend YieldN/A
Beta-0.27
Zafgen, Inc., a clinical-stage biopharmaceutical company, develops therapies for patients suffering from metabolic diseases comprising type 2 diabetes, Prader-Willi syndrome (PWS), and other metabolically related disorders. The company's lead product candidate is ZGN-1061, a fumagillin-class methionine aminopeptidase 2 (MetAP2) inhibitor administered by subcutaneous injection, which is in Phase 2 clinical trial and profiled for its utility in the treatment of type 2 diabetes and other related metabolic disorders. It also develops ZGN-1258, a MetAP2 inhibitor for treatment of PWS. Zafgen, Inc. was founded in 2005 and is headquartered in Boston, Massachusetts.
Read More
Zafgen logo

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ZFGN
CUSIPN/A
Phone617-622-4003

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$1.43 per share

Profitability

Net Income$-45,410,000.00

Miscellaneous

Employees38
Market Cap$30.31 million
Next Earnings Date5/14/2020 (Estimated)
OptionableOptionable

Receive ZFGN News and Ratings via Email

Sign-up to receive the latest news and ratings for ZFGN and its competitors with MarketBeat's FREE daily newsletter.


Zafgen (NASDAQ:ZFGN) Frequently Asked Questions

How has Zafgen's stock been impacted by COVID-19 (Coronavirus)?

Zafgen's stock was trading at $0.8501 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, ZFGN shares have decreased by 4.8% and is now trading at $0.8089. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Zafgen?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Zafgen in the last year. There are currently 5 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Zafgen.

When is Zafgen's next earnings date?

Zafgen is scheduled to release its next quarterly earnings announcement on Thursday, May 14th 2020. View our earnings forecast for Zafgen.

How were Zafgen's earnings last quarter?

Zafgen Inc (NASDAQ:ZFGN) posted its quarterly earnings results on Thursday, March, 5th. The biopharmaceutical company reported ($0.19) earnings per share for the quarter, hitting the Thomson Reuters' consensus estimate of ($0.19). View Zafgen's earnings history.

What price target have analysts set for ZFGN?

5 equities research analysts have issued 12 month target prices for Zafgen's stock. Their forecasts range from $0.78 to $8.00. On average, they expect Zafgen's share price to reach $4.59 in the next year. This suggests a possible upside of 467.8% from the stock's current price. View analysts' price targets for Zafgen.

Has Zafgen been receiving favorable news coverage?

News articles about ZFGN stock have trended very positive recently, according to InfoTrie. InfoTrie identifies negative and positive news coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Zafgen earned a media sentiment score of 4.0 on InfoTrie's scale. They also gave news headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the company's share price in the next several days. View the latest news aboutZafgen.

Are investors shorting Zafgen?

Zafgen saw a drop in short interest in February. As of February 28th, there was short interest totaling 565,000 shares, a drop of 38.7% from the February 13th total of 921,700 shares. Based on an average daily trading volume, of 623,900 shares, the days-to-cover ratio is presently 0.9 days. Approximately 1.7% of the company's shares are short sold. View Zafgen's Current Options Chain.

Who are some of Zafgen's key competitors?

What other stocks do shareholders of Zafgen own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Zafgen investors own include CA (CA), Endologix (ELGX), SCYNEXIS (SCYX), Energy Transfer LP Unit (ET), TG Therapeutics (TGTX), BlackRock (BLK), Fate Therapeutics (FATE), Gilead Sciences (GILD), Micron Technology (MU) and AT&T (T).

Who are Zafgen's key executives?

Zafgen's management team includes the following people:
  • Mr. Jeffrey S. Hatfield, CEO & Director (Age 61)
  • Ms. Patricia L. Allen, Chief Financial Officer (Age 57)
  • Dr. Dennis D. Kim M.D., MBA, Chief Medical Officer (Age 49)
  • Dr. James E. Vath, Head of Discovery & Devel. (Age 58)
  • Mr. Brian P. McVeigh, Chief Bus. Officer (Age 46)

What is Zafgen's stock symbol?

Zafgen trades on the NASDAQ under the ticker symbol "ZFGN."

Who are Zafgen's major shareholders?

Zafgen's stock is owned by a number of retail and institutional investors. Top institutional investors include Renaissance Technologies LLC (6.38%), Russell Investments Group Ltd. (1.06%), Point72 Asset Management L.P. (0.55%), Virtu Financial LLC (0.28%), Wedbush Securities Inc. (0.23%) and Jane Street Group LLC (0.16%). View institutional ownership trends for Zafgen.

Which major investors are selling Zafgen stock?

ZFGN stock was sold by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., Wedbush Securities Inc., and State Street Corp. View insider buying and selling activity for Zafgen.

Which major investors are buying Zafgen stock?

ZFGN stock was bought by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Renaissance Technologies LLC, Russell Investments Group Ltd., Virtu Financial LLC, and Jane Street Group LLC. View insider buying and selling activity for Zafgen.

How do I buy shares of Zafgen?

Shares of ZFGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Zafgen's stock price today?

One share of ZFGN stock can currently be purchased for approximately $0.81.

How big of a company is Zafgen?

Zafgen has a market capitalization of $30.31 million. The biopharmaceutical company earns $-45,410,000.00 in net income (profit) each year or ($1.07) on an earnings per share basis. Zafgen employs 38 workers across the globe. View additional information about Zafgen.

What is Zafgen's official website?

The official website for Zafgen is http://www.zafgen.com/.

How can I contact Zafgen?

Zafgen's mailing address is 3 Center Plaza Suite 610, BOSTON MA, 02108. The biopharmaceutical company can be reached via phone at 617-622-4003 or via email at [email protected]


MarketBeat Community Rating for Zafgen (NASDAQ ZFGN)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  343 (Thanks for Voting!)
Underperform Votes:  316 (Thanks for Voting!)
Total Votes:  659
MarketBeat's community ratings are surveys of what our community members think about Zafgen and other stocks. Vote "Outperform" if you believe ZFGN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ZFGN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/30/2020 by MarketBeat.com Staff

Featured Article: Options Trading

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel